Cea M, Cagnetta A, Garuti A, Cirmena G, Rocco I, Moran E, Grillo V, Ballestrero A, Patrone F, Nencioni A
Department of Internal Medicine, University of Genoa, Genoa, Italy.
J BUON. 2009 Oct-Dec;14(4):565-73.
The current treatment of chronic myelogenous leukemia (CML) is one of the most successful examples of molecularly targeted therapy in cancer. The identification of the fusion oncogene BCR-ABL allowed the discovery of small molecule inhibitors of its tyrosine kinase activity which, in turn, have literally revolutionized the treatment of this disease. However, large part of a successful clinical management of CML relies on appropriate diagnosis, molecular monitoring and identification of mutations potentially leading to drug resistance. These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored.
慢性髓性白血病（CML）的当前治疗是癌症分子靶向治疗最成功的例子之一。融合致癌基因BCR-ABL的鉴定使得能够发现其酪氨酸激酶活性的小分子抑制剂，这反过来又彻底改变了这种疾病的治疗方法。然而，CML成功临床管理的很大一部分依赖于适当的诊断、分子监测以及对可能导致耐药性的突变的鉴定。本文将讨论这些问题，并概述接受酪氨酸激酶抑制剂治疗的患者应如何进行监测。
